Bardin Hill Management Partners LP Invests $10.32 Million in Catalent, Inc. (NYSE:CTLT)

Bardin Hill Management Partners LP acquired a new position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 170,380 shares of the company's stock, valued at approximately $10,320,000. Catalent comprises about 4.8% of Bardin Hill Management Partners LP's investment portfolio, making the stock its 6th biggest position. Bardin Hill Management Partners LP owned about 0.09% of Catalent as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd bought a new position in Catalent in the 3rd quarter worth approximately $1,131,000. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Catalent by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company's stock valued at $24,550,000 after purchasing an additional 14,373 shares in the last quarter. Quest Partners LLC increased its stake in shares of Catalent by 289.8% in the third quarter. Quest Partners LLC now owns 49,300 shares of the company's stock worth $2,986,000 after acquiring an additional 36,652 shares during the last quarter. Swedbank AB acquired a new position in shares of Catalent in the first quarter worth $1,659,000. Finally, Natixis Advisors LLC acquired a new position in shares of Catalent in the third quarter worth $1,287,000.

Insider Activity at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Mcerlane sold 1,994 shares of the company's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 over the last quarter. Corporate insiders own 0.31% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on CTLT. StockNews.com downgraded shares of Catalent from a "hold" rating to a "sell" rating in a research note on Friday, November 22nd. William Blair reissued a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Baird R W downgraded shares of Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Finally, Robert W. Baird reaffirmed a "neutral" rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $63.40.

Catalent Stock Performance

Shares of NYSE CTLT traded up $0.28 during mid-day trading on Monday, hitting $61.39. The company had a trading volume of 1,063,063 shares, compared to its average volume of 2,026,623. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The business's 50-day simple moving average is $59.90 and its 200-day simple moving average is $58.51. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $61.50. The firm has a market cap of $11.14 billion, a P/E ratio of -27.04, a PEG ratio of 2.43 and a beta of 1.16.

Catalent (NYSE:CTLT - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.10) EPS. As a group, analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.